Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Moodys
US Army
Cerilliant
UBS
McKesson
Cipla
Baxter
Cantor Fitzgerald
Fuji

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,308,264

« Back to Dashboard

Summary for Patent: 4,308,264
Title: Stabilized, dilute aqueous preparation of 1.alpha.,25-dihydroxycholecalciferol for neonatal administration
Abstract:1.alpha.,25-Dihydroxycholecalciferol, also known as 1.alpha.,25-dihydroxyvitamin D.sub.3, calcitriol or 1.alpha.,25(OH).sub.2 D.sub.3, occurs naturally in man as the active form of cholecalciferol or vitamin D.sub.3. The natural supply of vitamin D.sub.3 depends on the conversion of 7-dehydrocholesterol to vitamin D.sub.3 in the skin by ultraviolet light. Vitamin D.sub.3 is then converted to calcitriol in a two-step process in the liver and kidney before its acts on its target tissue.
Inventor(s): Conway; Nancy M. (Mundelein, IL), Krimen; Lewis I. (Lake Bluff, IL)
Assignee: Abbott Laboratories (North Chicago, IL)
Application Number:06/228,870
Patent Claim Types:
see list of patent claims
Use; Compound; Dosage form; Composition; Formulation; Process;

Drugs Protected by US Patent 4,308,264

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 4,308,264

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 549765 ➤ Subscribe
Australia 7961382 ➤ Subscribe
Canada 1174605 ➤ Subscribe
Switzerland 651208 ➤ Subscribe
Germany 3202622 ➤ Subscribe
France 2498450 ➤ Subscribe
United Kingdom 2091556 ➤ Subscribe
Israel 64798 ➤ Subscribe
Japan S57144218 ➤ Subscribe
Japan S6144845 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
McKesson
Deloitte
Moodys
Covington
QuintilesIMS
Colorcon
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot